Immunotherapy (IT) and especially immune checkpoint blockade with PD1-(programmed cell death-1)/programmed cell death-ligand 1 (PD-L1) and CTLA-4 (cytotoxic T-lymphocyte-associated Protein 4) inhibitors have invaded the clinical routine and is revolutionizing the treatment of cancer. The gene discussed is CD274; the disease is cancer.